1. Discovery of novel 3-butyl-6-benzyloxyphthalide Mannich base derivatives as multifunctional agents against Alzheimer's disease.
- Author
-
Liu Z, Shi Y, Zhang X, Yu G, Li J, Cong S, and Deng Y
- Subjects
- Acetylcholinesterase metabolism, Alzheimer Disease metabolism, Animals, Blood-Brain Barrier drug effects, Blood-Brain Barrier metabolism, Cholinesterase Inhibitors chemical synthesis, Cholinesterase Inhibitors chemistry, Dose-Response Relationship, Drug, Electrophorus, Humans, Mannich Bases chemical synthesis, Mannich Bases chemistry, Molecular Structure, Monoamine Oxidase metabolism, Monoamine Oxidase Inhibitors chemical synthesis, Monoamine Oxidase Inhibitors chemistry, Neuroprotective Agents chemical synthesis, Neuroprotective Agents chemistry, Oxidative Stress drug effects, Structure-Activity Relationship, Alzheimer Disease drug therapy, Cholinesterase Inhibitors pharmacology, Drug Discovery, Mannich Bases pharmacology, Monoamine Oxidase Inhibitors pharmacology, Neuroprotective Agents pharmacology
- Abstract
Based on the multitarget-directed ligands strategy, a series of 3-butyl-6-benzyloxyphthalide Mannich base derivatives were designed, synthesized and identified for Alzheimer's disease (AD). Biological activity studies demonstrated that the designed hybrids showed multitarget activities toward AD. Among them, compound 7d was the most potent agent with excellent inhibitory activities on EeAChE (IC
50 = 0.087 μM), HuAChE (IC50 = 0.041 μM) and MAO-B (IC50 = 0.30 μM). Furthermore, molecular docking studies were conducted to investigate the interaction mode with enzymes. Besides, 7d also possessed good effects of Cu2+ chelation, ameliorate oxidative stress, and anti-neuroinflammation, desirable BBB permeability and eligible drug-like properties. Altogether, the multifunctional profiles of 7d prove that it deserves further investigation as a novel drug candidate for AD treatment., (Copyright © 2022 Elsevier Ltd. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF